(Q43023977)

12 November 2017

title

Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros (English)

1 reference

12 November 2017

1 reference

1

0 references

publication date

1 July 2010

1 reference

Digestive and Liver Disease

12 November 2017

published in

1 reference

12 November 2017

volume

42 Suppl 3

1 reference

12 November 2017

page(s)

S293-7

1 reference

Hepatitis B virus infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Hepatitis B surface antigen seroclearance during chronic HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Hepatitis B virus-related cirrhosis: natural history and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Role of viral factors in the natural course and therapy of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Natural history of chronic hepatitis B virus infection and long-term outcome under treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960519-1

7 January 2021

10.1016/S1590-8658(10)60519-1

Identifiers

DOI

1 reference

12 November 2017

1 reference